Allergy最新文献

{"title":"A Distinct Genetic Signature Differentiates Inflamed and Noninflamed Fibrotic Tissues in Eosinophilic Esophagitis Patients.","authors":"Emilie Gueguen, Yasser Morsy, Luc Biedermann, Alex Straumann, Michael Scharl, Marcin Wawrzyniak","doi":"10.1111/all.16497","DOIUrl":"https://doi.org/10.1111/all.16497","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143373659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Almost Half of the Dupilumab-Treated Patients With Severe Chronic Rhinosinusitis With Nasal Polyps Achieve Remission in One Year","authors":"Josje J. Otten, Hester E. Elzinga, Rik J. L. van der Lans, Wytske J. Fokkens, Sietze Reitsma, PolyREG Consortium","doi":"10.1111/all.16496","DOIUrl":"10.1111/all.16496","url":null,"abstract":"<p>The advent of biological therapeutics has revolutionized the field of primary diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). Dupilumab was the first to be available since late 2019. In line with the phase III trials, it has a high efficacy for otherwise severe and uncontrolled patients in real-world studies [<span>1</span>]. Data from our national database (PolyREG) show that dupilumab enables fast disease control within 6 months of treatment [<span>2</span>], and that this effect is maintained up to 2 years of follow-up, even when extending the dosing interval [<span>3</span>]. The field is now moving from the previous goal of treatment (disease control) to more audacious standards such as remission, or even cure, for which the EPOS/EUFOREA group recently proposed definitions [<span>4</span>].</p><p>We have performed an additional analysis of data previously published from our dupilumab cohort of 228 patients (214 with a follow-up of 1, and 99 of 2 years; all with informed consent) [<span>3</span>]. We translated the definitions on disease states into practical cut-offs (Appendix S1). Briefly, disease control (no bothersome complaints for the last month) was determined from patient-reported outcomes, while remission (sustained control for 12 months) was assessed using a combination of disease control, nasal endoscopy, and rescue treatments. Control and remission were determined after 1 and 2 years of treatment.</p><p>After 1 year, 63.9% met the criteria for disease control. Combined with nasal endoscopy and rescue treatments, 45.7% achieved remission. After 2 years of treatment, 50.0% of patients attained disease control and 43.7% was in remission. In patients where full data were available for both time points, 35.7% was in stable remission from the first year onwards (Table 1).</p><p>Tables S1 and S2 list baseline characteristics of control and remission groups per time point, respectively. Overall, no relevant differences between the groups were found at both 1- and 2-year follow-up. Notably, baseline blood eosinophils and total serum immunoglobulin E were not different between groups.</p><p>As tapering of the interdose interval was applied only in case of clinical control, there were significantly more patients with intervals of over 6 weeks in the remission group (71.0%; 22/31) than in the non-remission group (35%; 14/40; <i>p</i> = 0.004, chi-square) at 2 years. In other words, this suggests that tapering per se does not hamper remission when used in controlled patients only.</p><p>A prior history of olfactory response to oral corticosteroids (OCS) [<span>5</span>] only influenced the control rate at Year 1. Of note, 20%–50% of patients lacking control (precluding remission) solely due to olfactory dysfunction had no prior OCS-responsiveness (Table S3). This suggests irreversible anosmia as a direct result of CRSwNP itself or its treatment (surgery), or due to other causes (e.g., post-viral anosmia). As such, the infl","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 4","pages":"1166-1168"},"PeriodicalIF":12.6,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16496","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between N‐Glycan GnGnXF3 and the Allergic Immune Response Against Juniperus ashei Pollen","authors":"Javier Álvarez, Nuria Parody, David Calzada, Tamara Aranda, Ana Renshaw, Sonia Serna, Niels Reichardt, Juan María Beitia, David González‐de‐Olano, Javier Dominguez‐Ortega, Jerónimo Carnés","doi":"10.1111/all.16475","DOIUrl":"https://doi.org/10.1111/all.16475","url":null,"abstract":"BackgroundCupressaceae pollen increasingly causes respiratory allergies worldwide. Carbohydrates are abundant in extracts of these pollens, and the associated allergens are highly glycosylated. However, the contribution of saccharides to the allergenicity of these species remains unknown.Methods<jats:styled-content style=\"fixed-case\"><jats:italic>Juniperus ashei</jats:italic></jats:styled-content> pollen extract was deglycosylated and characterised using SDS‐PAGE and immunoblotting. Additionally, N‐ and O‐glycans were purified from the extract, identified, used as inhibitors in IgE‐immunoblotting and further analysed via basophil activation tests. The interactions between IgE and <jats:styled-content style=\"fixed-case\"><jats:italic>J. ashei</jats:italic></jats:styled-content> glycans were analysed using a glycan array. Purified Jun a 1 was treated with β‐N‐acetylglucosaminidase S and analysed using immunoblotting. The native pollen extract was used to immunise rabbits, and the IgG response was analysed using ELISA and glycan array.ResultsDeglycosylation of <jats:styled-content style=\"fixed-case\"><jats:italic>J. ashei</jats:italic></jats:styled-content> proteins abolished the interaction between IgE and allergens. This effect primarily depends on N‐glycans. Purified N‐glycans triggered basophil activation in some patients. A biantennary N‐glycan with terminal GlcNAc, β‐1,2 xylose and core α‐1,3 fucose (GnGnXF3) was the most abundant glycan identified. The glycan array confirmed its interaction with IgE. The contribution of terminal N‐acetylglucosamines (GlcNAc) to IgE–Jun a 1 interaction was validated. Moreover, effective immunisation of rabbits with the native extract confirmed the immunogenicity of their N‐glycans.ConclusionsThe IgE–<jats:styled-content style=\"fixed-case\"><jats:italic>J. ashei</jats:italic></jats:styled-content> allergen interaction is broadly controlled through N‐glycans different from MUXF3. GnGnXF3 exerts an immunogenic effect in humans and rabbits; terminal GlcNAc residues influence its recognition by IgE. These discoveries reinforce the role of N‐glycans in the allergic response to <jats:styled-content style=\"fixed-case\"><jats:italic>J. ashei</jats:italic></jats:styled-content>.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"28 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenome-Wide Association Study of Asthma Exacerbations in Europeans","authors":"Elena Martin-Gonzalez,&nbsp;Javier Perez-Garcia,&nbsp;Esther Herrera-Luis,&nbsp;Mario Martin-Almeida,&nbsp;Simon Kebede-Merid,&nbsp;Natalia Hernandez-Pacheco,&nbsp;Fabian Lorenzo-Diaz,&nbsp;Ruperto González-Pérez,&nbsp;Olaia Sardón,&nbsp;José M. Hernández-Pérez,&nbsp;Paloma Poza-Guedes,&nbsp;Inmaculada Sánchez-Machín,&nbsp;Elena Mederos-Luis,&nbsp;Paula Corcuera,&nbsp;Leyre López-Fernández,&nbsp;Berta Román-Bernal,&nbsp;Antoaneta A. Toncheva,&nbsp;Susanne Harner,&nbsp;Christine Wolff,&nbsp;Susanne Brandstetter,&nbsp;Mahmoud Ibrahim Abdel-Aziz,&nbsp;Simone Hashimoto,&nbsp;Susanne J. H. Vijverberg,&nbsp;Aletta D. Kraneveld,&nbsp;Uroš Potočnik,&nbsp;Michael Kabesch,&nbsp;Anke H. Maitland-van der Zee,&nbsp;Jesús Villar,&nbsp;Erik Melén,&nbsp;Maria Pino-Yanes","doi":"10.1111/all.16490","DOIUrl":"10.1111/all.16490","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Asthma exacerbations (AEs) represent the major contributor to the global asthma burden. Although genetic and environmental factors have been associated with AEs, the role of epigenetics remains uncovered.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to identify whole blood DNA methylation (DNAm) markers associated with AEs in Europeans.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>DNAm was assessed in 406 blood samples from Spanish individuals using the Infinium MethylationEPIC microarray (Illumina). An epigenome-wide association study was conducted to test the association of DNAm with AEs at differentially methylated positions, regions, and epigenetic modules. CpGs suggestively associated with AEs (false discovery rate [FDR] &lt; 0.1) were followed up for replication in 222 European individuals, and the genome-wide significance (<i>p</i> &lt; 9 × 10⁻⁸) was declared after meta-analyzing the discovery and replication samples. Additional assessment was performed using nasal tissue DNAm data from 155 Spanish individuals. The effects of genetic variation on DNAm were assessed through cis-methylation quantitative trait loci (meQTL) analysis. Enrichment analyses of previous EWAS signals were conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four CpGs were associated with AEs, and two were replicated and reached genomic significance in the meta-analysis (annotated to <i>ZBTB16</i> and <i>BAIAP2</i>). Of those, CpG cg25345365 (<i>ZBTB16</i>) was cross-tissue validated in nasal epithelium (<i>p</i>= 0.003) and associated with five independent meQTLs (FDR &lt; 0.05). Additionally, four differentially methylated regions and one module were significantly associated with AEs. Enrichment analyses revealed an overrepresentation of prior epigenetic associations with prenatal and environmental exposures, immune-mediated diseases, and mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>DNAm in whole blood and nasal samples may contribute to AEs in Europeans, capturing genetic and environmental risk factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 4","pages":"1086-1099"},"PeriodicalIF":12.6,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143187699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six Injections of Modified Adjuvanted PQ Grass Is Effective and Well-Tolerated in a Pivotal Phase III Trial.","authors":"Stefan Zielen, Jonathan A Bernstein, Gunter J Sturm, Marek Jutel, Oliver Pfaar, Mohamed H Shamji, Ralph Mösges, Markus Berger, Uwe E Berger, Lawrence DuBuske, Janice A Layhadi, Ludger Klimek, Markus Ollert, Murray A Skinner, Matthias F Kramer, Pieter-Jan de Kam","doi":"10.1111/all.16491","DOIUrl":"https://doi.org/10.1111/all.16491","url":null,"abstract":"<p><strong>Background: </strong>PQ Grass 27600 SU (PQ Grass) cumulative dose is a pre-seasonal, six-injection, aluminium-free, modified subcutaneous immunotherapy product under development for the treatment of allergic rhinitis (AR). A pivotal Phase III randomised double-blind, placebo-controlled clinical trial was performed to evaluate the efficacy and safety of PQ Grass in subjects with seasonal AR.</p><p><strong>Methods: </strong>An adaptive group sequential trial PQGrass306 (G306) with one pre-defined interim analysis was designed, using 2 parallel groups applying a 1:1 active versus placebo randomisation of patients aged 18-65. The primary efficacy endpoint was the EAACI (European Academy of Allergy and Clinical Immunology) Combined Symptom and Medication Score (EAACI-CSMS_0-6) averaged over the peak grass pollen season (GPS).</p><p><strong>Results: </strong>858 subjects were screened and 555 subjects were randomised. Based on the results of the pre-defined interim analysis, the trial was stopped for success showing superiority in favour of PQ Grass. The primary endpoint EAACI-CSMS_0-6 (peak GPS) demonstrated a highly significant and clinically meaningful point difference of PQ Grass over placebo of -0.27 points (95% CI: -0.42 to -0.12), corresponding to a relative difference of -20.3% (p = 0.0005). Highly consistent and beneficial results were obtained for PQ Grass for all key secondary endpoints. Significant induction of blocking IgG4 and IgA antibody subclasses occurred. PQ Grass was well tolerated, and no unexpected safety signals occurred.</p><p><strong>Conclusions: </strong>This pivotal Phase III trial demonstrated a significant and clinically meaningful effect on the primary endpoint as well as highly consistent secondary endpoint results and a supportive safety profile.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143187719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Phenotypically Distinct Human Th2 Cell Subpopulation Is Associated With Development of Allergic Disorders in Infancy","authors":"Catherine R. Pizzarello,&nbsp;Courtney M. Jackson,&nbsp;Katherine Herman,&nbsp;Antti E. Seppo,&nbsp;Jonathan Rebhahn,&nbsp;Tyler Scherzi,&nbsp;M. Cecilia Berin,&nbsp;R. John Looney,&nbsp;Tim R. Mosmann,&nbsp;Kirsi M. Järvinen","doi":"10.1111/all.16489","DOIUrl":"10.1111/all.16489","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Little is known about the ontogeny of T cell immunity during infancy in farming and urban lifestyles due to the lack of immunophenotyping in such birth cohorts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two birth cohorts (farming and urban) at differing risks and rates of allergic diseases were compared. Blood mononuclear cells were collected from infants at birth, and 6 and 12 months of age. Full spectrum flow cytometry, followed by traditional gating and the Scalable Weighted Iterative Flow-clustering Technique (SWIFT) high-dimensional analysis, were used to identify cell populations that differed between farming and urban infants. Additionally, single-cell RNAseq and multiplex cytokine assays were used to assess the function of cell populations of interest.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Several regulatory T cell (Treg) subpopulations were elevated in farming lifestyles and in non-atopic infants. A unique effector memory CD25⁺CD127⁺CD161⁻CD49d⁺CCR4⁺CRTH2⁺ Th2 population was elevated at 6 months in urban infants and in those who developed atopic dermatitis and/or food allergy and allergic sensitization. Although this population shared Th2 and IL-9 skewing with Th2A cells, the population uniquely failed to express CD161, produced more IL-2 and TNF-α, and upregulated the differentially expressed genes (DEGs), <i>FOXP3</i> and the cytokine inducible SH2-containing protein gene (<i>CISH</i>) relative to Th2A cells. This population has been termed Th2B cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We describe a unique effector memory Th2 population elevated in urban high-risk infants, potentially implicated in the development of allergic disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 4","pages":"949-964"},"PeriodicalIF":12.6,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143077990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Heat Exposure and Anaphylaxis in Japan: A Time‐Stratified Case‐Crossover Study","authors":"Nobutoshi Nawa, Hisaaki Nishimura, Kiyohide Fushimi, Takeo Fujiwara","doi":"10.1111/all.16488","DOIUrl":"https://doi.org/10.1111/all.16488","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"207 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Immune Regulation by Intralymphatic Immunotherapy With Modular Allergen Translocation MAT Vaccine”","authors":"","doi":"10.1111/all.16494","DOIUrl":"10.1111/all.16494","url":null,"abstract":"<p>“Immune Regulation by Intralymphatic Immunotherapy With Modular Allergen Translocation MAT Vaccine” (https://doi.org/10.1111/all.12461) in the <i>Allergy</i>.</p><p>A. Zaleska, T. Eiwegger, Ö. Soyer, W. van de Veen, C. Rhyner, M. B. Soyka, C. Bekpen, D. Demiroz, A. Treis, S. Söllner, O. Palomares, W. W. Kwok, H. Rose, G. Senti, T. M. Kündig, N. Ozoren, M. Jutel, C. A. Akdis, R. Crameri &amp; M. Akdis.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":"80 3","pages":"912"},"PeriodicalIF":12.6,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/all.16494","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143072933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral and Gut Microbial Hubs Associated With Reaction Threshold Interact With Circulating Immune Factors in Peanut Allergy.","authors":"Lingdi Zhang, Yoojin Chun, Galina Grishina, Tracy Lo, Kyle Reed, Julie Wang, Scott Sicherer, M Cecilia Berin, Supinda Bunyavanich","doi":"10.1111/all.16481","DOIUrl":"10.1111/all.16481","url":null,"abstract":"<p><strong>Background: </strong>Among peanut-allergic individuals, there is high variability in the amount of peanut that triggers reactions (i.e., reaction threshold) that is not predictable or well-understood. We conducted this study to characterize relationships between the oral and gut microbiomes and systemic processes associated with reaction threshold in peanut allergy (PA).</p><p><strong>Methods: </strong>In a cohort of 120 children with suspected PA who underwent double-blind, placebo-controlled food challenges, we generated and analyzed parallel profiles of the oral microbiome, gut microbiome, peripheral blood transcriptome, peripheral blood cytometry, and serum antibody levels to identify threshold-associated markers and their inter-relationships.</p><p><strong>Results: </strong>The 120 participants included 23 children with no PA, 74 with high-threshold PA (reacting to ≥ 443 mg cumulative peanut protein), and 23 with low-threshold PA (reacting to < 443 mg cumulative peanut protein). Ten hub microbes were each identified in saliva and stool microbiome networks that were constructed, including the hub microbes Rothia aeria in saliva and Bacteroides sp. in stool that were associated with reaction threshold. These hub microbes were also associated with peripheral blood transcript levels for threshold-associated key drivers of FcγR-mediated phagocytosis and TLR signaling. Correlation network construction with additional data on threshold-associated peripheral blood neutrophil abundance and peanut-specific serum IgE and Ara h 2 antibody levels revealed central roles for saliva Rothia aeria and stool Bacteroides sp. in local-systemic networks for IgE- and IgG-mediated peanut allergy.</p><p><strong>Conclusions: </strong>This integrated study of oral and stool microbiomes, blood transcriptome, cellular profiles, and peanut-specific serum antibodies revealed new relationships between local microbiota and systemic measures associated with reaction threshold in peanut allergy.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143062577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dichotomous STAT5 and STAT6 Activation in T Cells Reflects Cytokine Shifts Between Blood and Skin in Atopic Dermatitis.","authors":"Andreas Boldt, Regina Treudler, Marie Rabe, Niklas Artz, Sabine Seiffert, Rachael Bogle, Xianying Xing, Louise Wilkens, Ariane Bialas, Lea Präger, Lam C Tsoi, Ulrike Koehl, Sandra Franz, Sonja Grunewald, Jan C Simon, J Michelle Kahlenberg, Johann E Gudjonsson, Benjamin Klein","doi":"10.1111/all.16492","DOIUrl":"https://doi.org/10.1111/all.16492","url":null,"abstract":"<p><p>We assessed STAT activation in T cells in blood and skin of AD patients versus HC. pSTAT5⁺ T cells were increased in AD blood, correlated with disease activity, and were induced by common γc cytokines. Skin T cells exhibited a STAT6 signature, whereas only a subset was positive for STAT5. AD, atopic dermatitis; HC, healthy controls; STAT: Signal Transducers and Activators of Transcription.</p>","PeriodicalId":122,"journal":{"name":"Allergy","volume":" ","pages":""},"PeriodicalIF":12.6,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143062568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}